126 related articles for article (PubMed ID: 33041188)
1. Stratifying patients with intermediate-risk prostate cancer: Validation of a new model based on MRI parameters and targeted biopsy and comparison with NCCN and AUA subclassifications.
Diamand R; Ploussard G; Roumiguié M; Malavaud B; Oderda M; Gontero P; Fourcade A; Fournier G; Benamran D; Iselin C; Fiard G; Descotes JL; Peltier A; Simone G; Roche JB; Roumeguère T; Albisinni S
Urol Oncol; 2021 May; 39(5):296.e1-296.e9. PubMed ID: 33041188
[TBL] [Abstract][Full Text] [Related]
2. Risk stratification for early biochemical recurrence of prostate cancer in the era of multiparametric magnetic resonance imagining-targeted biopsy.
Diamand R; Peltier A; Roche JB; Lievore E; Lacetera V; Chiacchio G; Beatrici V; Mastroianni R; Simone G; Windisch O; Benamran D; Fourcade A; Nguyen TA; Fournier G; Fiard G; Ploussard G; Roumeguère T; Albisinni S
Prostate; 2023 May; 83(6):572-579. PubMed ID: 36705314
[TBL] [Abstract][Full Text] [Related]
3. Improvement of the intermediate risk prostate cancer sub-classification by integrating MRI and fusion biopsy features.
Roumiguie M; Lesourd M; Zgheib J; Tollon C; Salin A; Alméras C; Doumerc N; Thoulouzan M; Soulié M; Gautier JR; Loison G; Assoun J; Vacher A; Aziza R; Malavaud B; Beauval JB; Ploussard G
Urol Oncol; 2020 May; 38(5):386-392. PubMed ID: 31948932
[TBL] [Abstract][Full Text] [Related]
4. The Key Combined Value of Multiparametric Magnetic Resonance Imaging, and Magnetic Resonance Imaging-targeted and Concomitant Systematic Biopsies for the Prediction of Adverse Pathological Features in Prostate Cancer Patients Undergoing Radical Prostatectomy.
Gandaglia G; Ploussard G; Valerio M; Mattei A; Fiori C; Roumiguié M; Fossati N; Stabile A; Beauval JB; Malavaud B; Scuderi S; Barletta F; Moschini M; Zamboni S; Rakauskas A; Tian Z; Karakiewicz PI; De Cobelli F; Porpiglia F; Montorsi F; Briganti A
Eur Urol; 2020 Jun; 77(6):733-741. PubMed ID: 31547938
[TBL] [Abstract][Full Text] [Related]
5. Defining Prostate Cancer at Favorable Intermediate Risk: The Potential Utility of Magnetic Resonance Imaging and Genomic Tests.
Falagario UG; Beksac AT; Martini A; Cumarasamy S; Gupta A; Prasad S; Thulasidass H; Shah QN; Jayaratna I; Lewis S; Rastinehad AR; Taouli B; Cormio L; Carrieri G; Tewari AK
J Urol; 2019 Jul; 202(1):102-107. PubMed ID: 30730408
[TBL] [Abstract][Full Text] [Related]
6. Prognostic Implications of Multiparametric Magnetic Resonance Imaging and Concomitant Systematic Biopsy in Predicting Biochemical Recurrence After Radical Prostatectomy in Prostate Cancer Patients Diagnosed with Magnetic Resonance Imaging-targeted Biopsy.
Gandaglia G; Ploussard G; Valerio M; Marra G; Moschini M; Martini A; Roumiguié M; Fossati N; Stabile A; Beauval JB; Malavaud B; Scuderi S; Barletta F; Afferi L; Rakauskas A; Gontero P; Mattei A; Montorsi F; Briganti A
Eur Urol Oncol; 2020 Dec; 3(6):739-747. PubMed ID: 32847747
[TBL] [Abstract][Full Text] [Related]
7. International Multicenter Validation of an Intermediate Risk Subclassification of Prostate Cancer Managed with Radical Treatment without Hormone Therapy.
Berlin A; Moraes FY; Sanmamed N; Glicksman R; Koven A; Espin-Garcia O; Leite ETT; Silva JLF; Gadia R; Nesbitt M; Catton CN; Kaffenberger S; Salami SS; Morgan TM; Hearn JWD; Jackson WC; Mehra R; Chung P; Fleshner NE; Zumsteg ZS; Dess RT; Feng FY; Finelli A; Spratt DE
J Urol; 2019 Feb; 201(2):284-291. PubMed ID: 30153435
[TBL] [Abstract][Full Text] [Related]
8. Expanding Active Surveillance Criteria for Low- and Intermediate-risk Prostate Cancer: Can We Accurately Predict the Risk of Misclassification for Patients Diagnosed by Multiparametric Magnetic Resonance Imaging-targeted Biopsy?
Diamand R; Albisinni S; Roche JB; Lievore E; Lacetera V; Chiacchio G; Beatrici V; Mastroianni R; Simone G; Windisch O; Benamran D; Fourcade A; An Nguyen T; Fournier G; Fiard G; Ploussard G; Peltier A; Roumeguère T
Eur Urol Focus; 2023 Mar; 9(2):298-302. PubMed ID: 36210296
[TBL] [Abstract][Full Text] [Related]
9. External Validation of a Multiparametric Magnetic Resonance Imaging-based Nomogram for the Prediction of Extracapsular Extension and Seminal Vesicle Invasion in Prostate Cancer Patients Undergoing Radical Prostatectomy.
Diamand R; Ploussard G; Roumiguié M; Oderda M; Benamran D; Fiard G; Quackels T; Assenmacher G; Simone G; Van Damme J; Malavaud B; Iselin C; Descotes JL; Roche JB; Peltier A; Roumeguère T; Albisinni S
Eur Urol; 2021 Feb; 79(2):180-185. PubMed ID: 33023770
[TBL] [Abstract][Full Text] [Related]
10. A 17-Gene Genomic Prostate Score Assay Provides Independent Information on Adverse Pathology in the Setting of Combined Multiparametric Magnetic Resonance Imaging Fusion Targeted and Systematic Prostate Biopsy.
Salmasi A; Said J; Shindel AW; Khoshnoodi P; Felker ER; Sisk AE; Grogan T; McCullough D; Bennett J; Bailey H; Lawrence HJ; Elashoff DA; Marks LS; Raman SS; Febbo PG; Reiter RE
J Urol; 2018 Sep; 200(3):564-572. PubMed ID: 29524506
[TBL] [Abstract][Full Text] [Related]
11. Improved decision making in intermediate-risk prostate cancer: a multicenter study on pathologic and oncologic outcomes after radical prostatectomy.
Beauval JB; Ploussard G; Cabarrou B; Roumiguié M; Ouzzane A; Gas J; Goujon A; Marcq G; Mathieu R; Vincendeau S; Cathelineau X; Mongiat-Artus P; Salomon L; Soulié M; Méjean A; de La Taille A; Rouprêt M; Rozet F;
World J Urol; 2017 Aug; 35(8):1191-1197. PubMed ID: 27987030
[TBL] [Abstract][Full Text] [Related]
12. Is pelvic MRI imaging sufficient cross-sectional imaging for staging intermediate and high-risk prostate cancer?
Grant Owens R; Loloi J; Lehman EB; Kaag MG; Raman JD; Merrill SB
Urol Oncol; 2021 Jul; 39(7):433.e9-433.e15. PubMed ID: 33610444
[TBL] [Abstract][Full Text] [Related]
13. Performance of prostate multiparametric MRI for prediction of prostate cancer extra-prostatic extension according to NCCN risk categories: implication for surgical planning.
Falagario UG; Jambor I; Ratnani P; Martini A; Treacy PJ; Wajswol E; Lantz A; Papastefanou G; Weil R; Phillip D; Lewis S; Haines K; Cormio L; Carrieri G; Kyprianou N; Wiklund P; Tewari AK
Minerva Urol Nefrol; 2020 Dec; 72(6):746-754. PubMed ID: 32182231
[TBL] [Abstract][Full Text] [Related]
14. Decreased accuracy of the prostate cancer EAU risk group classification in the era of imaging-guided diagnostic pathway: proposal for a new classification based on MRI-targeted biopsies and early oncologic outcomes after surgery.
Ploussard G; Manceau C; Beauval JB; Lesourd M; Almeras C; Gautier JR; Loison G; Salin A; Soulié M; Tollon C; Malavaud B; Roumiguié M
World J Urol; 2020 Oct; 38(10):2493-2500. PubMed ID: 31838560
[TBL] [Abstract][Full Text] [Related]
15. Performance characteristics of prostate-specific antigen density and biopsy core details to predict oncological outcome in patients with intermediate to high-risk prostate cancer underwent robot-assisted radical prostatectomy.
Yashi M; Nukui A; Tokura Y; Takei K; Suzuki I; Sakamoto K; Yuki H; Kambara T; Betsunoh H; Abe H; Fukabori Y; Nakazato Y; Kaji Y; Kamai T
BMC Urol; 2017 Jun; 17(1):47. PubMed ID: 28645325
[TBL] [Abstract][Full Text] [Related]
16. Genomic Classifier for Guiding Treatment of Intermediate-Risk Prostate Cancers to Dose-Escalated Image Guided Radiation Therapy Without Hormone Therapy.
Berlin A; Murgic J; Hosni A; Pintilie M; Salcedo A; Fraser M; Kamel-Reid S; Zhang J; Wang Q; Ch'ng C; Deheshi S; Davicioni E; van der Kwast T; Boutros PC; Bristow RG; Chua MLK
Int J Radiat Oncol Biol Phys; 2019 Jan; 103(1):84-91. PubMed ID: 30170099
[TBL] [Abstract][Full Text] [Related]
17. Adverse Disease Features in Gleason Score 3 + 4 "Favorable Intermediate-Risk" Prostate Cancer: Implications for Active Surveillance.
Morlacco A; Cheville JC; Rangel LJ; Gearman DJ; Karnes RJ
Eur Urol; 2017 Sep; 72(3):442-447. PubMed ID: 27574819
[TBL] [Abstract][Full Text] [Related]
18. Persistent Discordance in Grade, Stage, and NCCN Risk Stratification in Men Undergoing Targeted Biopsy and Radical Prostatectomy.
Alshak MN; Patel N; Gross MD; Margolis D; Hu JC
Urology; 2020 Jan; 135():117-123. PubMed ID: 31568795
[TBL] [Abstract][Full Text] [Related]
19. Improving the Stratification of Patients With Intermediate-risk Prostate Cancer.
Stolzenbach LF; Nocera L; Collà-Ruvolo C; Tian Z; Knipper S; Maurer T; Tilki D; Graefen M; Karakiewicz PI
Clin Genitourin Cancer; 2021 Apr; 19(2):e120-e128. PubMed ID: 33358891
[TBL] [Abstract][Full Text] [Related]
20. Risk-based Patient Selection for Magnetic Resonance Imaging-targeted Prostate Biopsy after Negative Transrectal Ultrasound-guided Random Biopsy Avoids Unnecessary Magnetic Resonance Imaging Scans.
Alberts AR; Schoots IG; Bokhorst LP; van Leenders GJ; Bangma CH; Roobol MJ
Eur Urol; 2016 Jun; 69(6):1129-34. PubMed ID: 26651990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
